2015-005120-26: A Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of GSK2140944 in the Treatment of Gonorrhea in Adults |
|
|
| Ongoing | 2 | 100 | Europe | GSK2140944 Capsules, 500 mg, Capsule, hard | GlaxoSmithKline Research and Development Limited, Department of Health and Human Services (HHS) | Uncomplicated urogenital gonorrhea, Gonorrhoea is an infection of genital area, Diseases [C] - Bacterial Infections and Mycoses [C01] | | | | |
2019-004308-37: Penetration of the innovative antibiotic gepotidacin into prostate and tonsillar tissue. |
|
|
| Not yet recruiting | 2 | 60 | Europe | Gepotidacin, Tablet | Institut National de la Santé et de la Recherche Médicale (INSERM), Innovative Medicines Initiative 2 (H2020 programme) | Cohort A: Male patients with localized prostate cancer scheduled to undergo radical prostatectomy and patients with benign prostate hyperplasia scheduled to undergo simple prostatectomy Cohort B: Male and female patients undergoing complete tonsillectomy Cohorte A* : Patients de sexe masculin atteints d’un cancer localisé de la prostate devant subir une prostatectomie totale (PT) et les patients atteints d’hyperplasie bénigne de la prostate (BPH) devant subir une prostatectomie simple Cohorte B : Patients de sexe masculin ou féminin devant faire l’objet d’une amygdalectomie totale *En France, seuls les patients avec BPH seront inclus dans la cohorte A, Cohort A: Male patients with localized prostate cancer and patients with benign prostate hyperplasia Cohort B: patients undergoing complete tonsillectomy, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Surgical Procedures, Operative [E04] | | | | |
